AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...

MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...

The shift towards new cell culture–based flu vaccine production has been dealt a blow as MedImmune of Gaithersburg, Maryland, puts its manufacturing efforts on hold. The AstraZeneca subsidiary ...

Executive Vice President, R&D, MedImmune, Gaithersburg, Maryland, USA. Prior to joining Medimmune in 2001, Peter Kiener, D. Phil., spent 18 years with the Pharmaceutical Research Division of ...